Over the last several years, numerous studies into cancer immunology have been conducted. For certain kinds of genitourinary (GU) solid tumors, such as ovarian cancer, cervical cancer, bladder cancer, and liver cancer, previous treatments are limited, relying on immunotherapy. However, due to low efficiency and developing drug resistance, these treatments have little effect in treating refractory GU and liver cancers. Understanding the mechanisms of action will be important for future clinical therapies in solid tumor treatment.
This Research Topic aims to address the following topical issues:
1. Whether non-conventional immune checkpoint proteins and newly developed markers can be used to identify and improve treatment of refractory GU and liver tumors
2. New mechanisms that would contribute to our understanding of the immunological biology of these refractory tumors
3. Identifying crosstalk between the tumor immunological biomarkers and cancer transcription factors
4. New technologies or strategies for improving the therapeutic effects or decreasing the drug resistance of cancer immunology therapy in the refractory GU and liver tumors
In this Research Topic, we would like to summarize the latest research in this area. We welcome Original Research, Review/Mini-Review, Systematic Review, Clinical Trial, and Case Report articles, focusing on, but not limited to:
1. The research progress on immune checkpoint inhibitors, especially newly developed markers such as Lag-3 and TIGIT and the effects on refractory ovarian cancer, cervical cancer, bladder cancer, and liver cancer
2. The application of new technologies on the immunology of GU and liver tumors. This could include PROTAC, molecular glue, gene therapy, new clinical combination therapy, ADC, PDC, and bio-specific antibodies
3. Possible mechanisms for the development of drug-resistance
4. Crosstalk between cancer transcription factors and immunological signaling pathways
Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases, which are not accompanied by robust and relevant validation (clinical cohort or biological validation in vitro or in vivo), are out of scope for this topic.
Over the last several years, numerous studies into cancer immunology have been conducted. For certain kinds of genitourinary (GU) solid tumors, such as ovarian cancer, cervical cancer, bladder cancer, and liver cancer, previous treatments are limited, relying on immunotherapy. However, due to low efficiency and developing drug resistance, these treatments have little effect in treating refractory GU and liver cancers. Understanding the mechanisms of action will be important for future clinical therapies in solid tumor treatment.
This Research Topic aims to address the following topical issues:
1. Whether non-conventional immune checkpoint proteins and newly developed markers can be used to identify and improve treatment of refractory GU and liver tumors
2. New mechanisms that would contribute to our understanding of the immunological biology of these refractory tumors
3. Identifying crosstalk between the tumor immunological biomarkers and cancer transcription factors
4. New technologies or strategies for improving the therapeutic effects or decreasing the drug resistance of cancer immunology therapy in the refractory GU and liver tumors
In this Research Topic, we would like to summarize the latest research in this area. We welcome Original Research, Review/Mini-Review, Systematic Review, Clinical Trial, and Case Report articles, focusing on, but not limited to:
1. The research progress on immune checkpoint inhibitors, especially newly developed markers such as Lag-3 and TIGIT and the effects on refractory ovarian cancer, cervical cancer, bladder cancer, and liver cancer
2. The application of new technologies on the immunology of GU and liver tumors. This could include PROTAC, molecular glue, gene therapy, new clinical combination therapy, ADC, PDC, and bio-specific antibodies
3. Possible mechanisms for the development of drug-resistance
4. Crosstalk between cancer transcription factors and immunological signaling pathways
Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases, which are not accompanied by robust and relevant validation (clinical cohort or biological validation in vitro or in vivo), are out of scope for this topic.
